The Right Rx Based on the Right Dx at the Right Time

The Oncomine™ Dx Target Test is the first FDA-approved targeted NGS that can detect multiple gene mutations for non-small cell lung cancer (NSCLC) to aid in the selection of specific targeted therapies for NSCLC patients. Learn More >>

Liquid::Lung-cfDNA^TM – Cell-Free DNA NGS Panel for Lung Cancer

CGI’s Liquid::Lung-cfDNA^TM,  cell-free DNA (cfDNA) liquid biopsy next generation sequencing (NGS) panel, is CLIA validated and available for both clinical care and for clinical trials being performed by biotech and pharmaceutical companies. 

Learn More >>

Focus::Oncomine^TM NGS Panel For Solid Tumors

CGI’s Focus::Oncomine^TM NGS panel is CLIA validated and available for both clinical care and for clinical trials being performed by biotech and pharmaceutical companies.  Learn More >>

CGI Now Offers FDA-cleared Tissue of Origin^® Test

The Tissue of Origin^® test, formally a Pathwork test, is a microarray-based gene expression test that aids in identifying challenging tumors, including metastatic, poorly differentiated, and undifferentiated cancers. It’s the only FDA-cleared test of its type, and is a Medicare-reimbursed test.  Learn More >>